KKKathryn J. Klopfenstein

Kathryn J. Klopfenstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kathryn J. Klopfenstein has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence of abnormal bone density of pediatric patients prior to blood or marrow transplant

    by Kathryn J. Klopfenstein, Julie Clayton, Robin Rosselet, Bryce Kerlin, Amanda Termuhlen, Thomas Gross

    Osteoporosis and osteopenia are long‐term side effects of bone marrow transplant (BMT). The purpose of this study was to determine the prevalence of bone mineral density (BMD) abnormalities in pediatric patients prior to BMT. Forty‐four pediatric patients were evaluated with DEXA scans. The average Z‐score was −0.37. Thirty‐six percent had abnormal BMD. Sixty‐seven percent of ALL patients had abnormal BMD. Patients with non‐malignant diseases were significantly more likely to have abnormal BMD. Patients with ALL had more defects than solid tumor patients. Females had more defects than males. These results demonstrate BMD defects are common in children prior to BMT, especially in patients with ALL. Pediatr Blood Cancer 2009;53:675–677.


  • Prolonged Survival With Continuous Infusion Topotecan

    by Kathryn J. Klopfenstein, Suzanne Scott, David E. Schuller, Frederick B. Ruymann

    Two patients with solid tumors were treated with 21-day continuous infusion topotecan as palliation therapy. Case 1: A 10-year-old girl was diagnosed with progressive, metastatic hepatocellular carcinoma. Twenty-one–day continuous infusion topotecan was started and she has had a partial response. Case 2: A 17-year-old girl developed a malignant fibrous histiocytoma as a second malignant neoplasm. After partial resection and failure of multiagent chemotherapy, she started continuous infusion topotecan and was disease-free for 58 months when she died of pneumonia. These cases suggest that topotecan given as 21-day continuous infusion is efficacious for palliation care.